Kagocel, tablets 12 mg 10 pcs

The main mechanism of action of Kagocel® is the ability to induce production of interferons. Kagocel® induces formation in human body of so-called late interferons, which are mixture of α- and β-interferons with high antiviral activity.

Kagocel® causes production of interferons in all cell populations participating in antiviral response of the body: T- and B- lymphocytes, macrophages, granulocytes, fibroblasts, endothelial cells. After a single dose of Kagocel® administration interferon titer in blood serum reaches its maximum value in 48 hours.

Interferon response to Kagocel® administration is characterized by prolonged (up to 4-5 days) circulation of interferons in blood stream. The dynamics of interferon accumulation in the intestine when taking Kagocel® does not coincide with the dynamics of circulating interferon titers. In serum interferon production reaches high values only in 48 hours after Kagocel® administration, while in intestine maximum interferon production is observed in 4 hours.

Kagocel® is not toxic when administered in therapeutic doses, it does not accumulate in the body. The drug has no mutagenic and teratogenic properties, is not carcinogenic and has no embryotoxic effect.

The highest effectiveness of Cagocel® treatment is observed when administered not later than the 4th day after the onset of acute infection. As a preventive measure the drug may be used at any time including immediately after contact with the infectious agent.

Pharmacokinetics

In 24 hours after injection Kagocel® accumulates in the body mainly in liver, to a lesser degree in lungs, thymus, spleen, kidneys, lymph nodes. Low concentration is noted in adipose tissue, heart, muscles, testes, brain, blood plasma.

Low content of Kagocel® in brain is due to the high molecular weight of the drug that prevents its penetration through the blood-brain barrier. In blood plasma the drug is mainly in bound form.

With daily repeated administration of Kagocel® distribution varies over a wide range in all organs studied. Accumulation of the drug in spleen and lymph nodes is especially pronounced. When administered orally about 20% of the administered drug dose enters the general bloodstream.

Absorbed drug circulates in blood mainly in macromolecule-bound form: with lipids – 47%, with proteins – 37%. The unbound part of the drug is about 16%.

Excretion

The drug is excreted mainly through the intestines: 88% of the administered dose is excreted from the body seven days after administration, including 90% – through the intestines and 10% – by the kidneys. The drug is not detected in the exhaled air.

Indications

Kagocel® is used in adults as a prophylactic and therapeutic agent for influenza and other acute respiratory viral infections (ARI), as well as a therapeutic agent for herpes.

Cagocel® is used in children over 6 years old as a prophylactic agent for flu and other acute respiratory viral infections.

Cagocel® is used in children over 3 years old as a treatment for flu and other acute respiratory viral infections.

Active ingredient

Kagocel

Composition

1 tablet contains:

The active ingredients:

cagocel 12 mgY

Associated substances:

potato starch – 10 mg,

calcium stearate – 0.65 mg,

ludipress (directly pressed lactose with the composition: lactose monohydrate, povidone (collidone 30),

crospovidone (collidone CL)) – to obtain a tablet with a weight of 100 mg.

How to take, the dosage

For oral use.

To treat flu and SARS, adults are prescribed for the first two days – 2 tablets of Kagocel 3 times a day, in the next two days – one tablet 3 times a day. A total of 18 tablets for the course, the duration of the course is 4 days.

The prevention of flu and SARS in adults is carried out in 7-day cycles: two days with 2 tablets once a day, a 5-day break, then the cycle is repeated. The duration of the prophylactic course is from one week to several months.

For the treatment of herpes in adults 2 tablets 3 times a day for 5 days are prescribed. A total of 30 tablets for the course, the duration of the course is 5 days.

For the treatment of flu and acute respiratory viral infections in children aged 3 to 6 years old prescribe 1 tablet of Kagocel 2 times a day for the first two days, and 1 tablet once a day for the next two days. A total of 6 pills for the course, the duration of the course is 4 days.

For the treatment of flu and acute respiratory infections in children aged 6 years and older, the first two days – 1 tablet 3 times a day, the next two days – 1 tablet 2 times a day. A total of 10 pills for the course, the duration of the course is 4 days.

The prophylaxis of influenza and acute respiratory viral infections in children at the age of 6 years is made in 7-day cycles: two days – 1 tablet of Kagocel 1 time per day, 5 days break, then the cycle is repeated. The duration of the prophylactic course is from one week to several months.

Interaction

Kagocel® combines well with other antiviral drugs, immunomodulators and antibiotics (additive effect).

Special Instructions

To achieve a therapeutic effect, start taking Kagocel® no later than the fourth day from the beginning of the disease.

Contraindications

Hypersensitivity, pregnancy, age less than 3 years, lactase deficiency, lactose intolerance, glucose-galactose malabsorption.

Side effects

Allergic reactions may develop.

Overdose

In case of an accidental overdose, it is recommended to give plenty of fluids and induce vomiting.